Paper Details

  1. Home
  2. Paper Details

DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.

Author: AchenbachJanosch, HeitelPascal, MerkDaniel, MoserDaniel, ProschakEwgenij

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study identified two marketed drugs, alitretinoin and bexarotene, as partial liver X receptor (LXR) agonists using in silico screening and in vitro testing. The study showed that plasma concentrations observed in clinical trials are sufficient for LXR activation, suggesting that these drugs could be responsible for LXR-mediated side effects like hypercholesterolemia. The findings open up possibilities for developing new LXR modulators with improved safety profiles.
Paper Details　
Original Abstract of the Article :
In silico screening of DrugBank database to detect liver X receptor (LXR) agonism of marketed drugs using a self-organizing map and successive LXR-Gal4 hybrid reporter gene assay evaluation in vitro discovered alitretinoin and bexarotene as partial liver X receptor agonists. Dose-response curves dem...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bmcl.2017.01.066

データ提供：米国国立医学図書館（NLM）

Unveiling Hidden Potential: Alitretinoin and Bexarotene as Liver X Receptor Modulators

This study delves into the intriguing world of drug repurposing, investigating the potential of existing medications for new therapeutic applications. The researchers utilized a computational approach to screen the DrugBank database for potential liver X receptor (LXR) agonists, identifying alitretinoin and bexarotene as promising candidates. These drugs, already used for treating skin conditions, were found to activate LXRs, which play a crucial role in lipid metabolism and inflammation. This discovery opens up new avenues for utilizing these existing drugs for managing conditions related to lipid metabolism and inflammation.

New Insights into Existing Drugs: A Treasure Trove of Potential

This study highlights the potential of drug repurposing, revealing hidden therapeutic properties of already approved medications. The identification of alitretinoin and bexarotene as LXR agonists suggests that these drugs could be repurposed for treating conditions related to lipid metabolism and inflammation. This approach not only saves time and resources but also offers the potential for faster clinical translation.

A Glimpse into the Future of Drug Development

This study exemplifies the power of computational approaches in drug discovery. By utilizing in silico screening methods, researchers can identify promising drug candidates and explore their potential for treating a broader range of conditions. This approach could revolutionize the drug development process, accelerating the discovery of new therapies and enhancing patient care.

Dr.Camel's Conclusion

Just like a desert explorer unearthing hidden treasures, this study reveals the potential of existing drugs for new therapeutic applications. The discovery of alitretinoin and bexarotene as LXR agonists opens up a new chapter in drug repurposing, offering a glimpse into the future of drug development and patient care.

Date :
  1. Date Completed 2017-08-18
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28169169

DOI: Digital Object Identifier

10.1016/j.bmcl.2017.01.066

Related Literature

Article Analysis
・Side Effects of alitretinoin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.